论文部分内容阅读
目的:探讨FK506作用下肠屏障功能的变化及意义。方法:比较免疫抑制组和对照组大鼠血浆D-乳酸和DAO浓度、回肠黏膜病理分析。结果:免疫抑制组血浆D-乳酸和DAO浓度、肠黏膜损伤评分在各时间点均呈缓慢上升趋势。与对照组比较,第3、5、7天血浆D-乳酸和DAO浓度、各时间点的肠黏膜损伤评分均显著增高(P<0.05)。血浆D-乳酸、DAO浓度与肠黏膜损伤评分之间呈显著正相关(P<0.05)。结论:FK506可以引起肠黏膜上皮损伤,肠黏膜机械屏障功能破坏,肠黏膜通透性增高。随FK506应用时间的延长,肠黏膜损伤的加重,肠黏膜通透性改变越显著。检测血浆D-乳酸和DAO的变化,能够及时反映免疫抑制剂引起的肠黏膜上皮损伤及其通透性变化。
Objective: To investigate the changes of intestinal barrier function under the action of FK506 and its significance. Methods: The plasma concentrations of D-lactate and DAO in immunosuppressed and control groups were compared. The pathological changes of ileal mucosa were analyzed. Results: The concentrations of D-lactate and DAO in plasma and the damage of intestinal mucosa in immunosuppressed group showed a slowly increasing trend at each time point. Compared with the control group, the concentrations of D-lactate and DAO on the 3rd, 5th and 7th day were significantly increased (P <0.05). Plasma D-lactate, DAO concentration and intestinal mucosal injury score was positively correlated (P <0.05). Conclusion: FK506 can cause injury of intestinal mucosa epithelium, damage of mechanical barrier of intestinal mucosa and increase of intestinal mucosa permeability. With the extension of FK506 application time, the intestinal mucosal injury increased, the more obvious change of intestinal mucosal permeability. Detecting the changes of plasma D-lactate and DAO, can promptly reflect the immunosuppressive agents induced intestinal epithelial damage and permeability changes.